Home Cart Sign in  
Chemical Structure| 939981-39-2 Chemical Structure| 939981-39-2

Structure of RG7112
CAS No.: 939981-39-2

Chemical Structure| 939981-39-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RG7112 is a potent, selective, first clinical, orally active MDM2-p53 inhibitor that crosses the blood-brain barrier, with an IC50 of 18 nM and a KD of 11 nM for binding to MDM2.

Synonyms: RO5045337

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RG7112

CAS No. :939981-39-2
Formula : C38H48Cl2N4O4S
M.W : 727.78
SMILES Code : C[C@@]1([C@](C)(N(C(C2=CC=C(C=C2OCC)C(C)(C)C)=N1)C(N3CCN(CC3)CCCS(=O)(C)=O)=O)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl
Synonyms :
RO5045337
MDL No. :MFCD18206914
InChI Key :QBGKPEROWUKSBK-QPPIDDCLSA-N
Pubchem ID :57406853

Safety of RG7112

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00623870 Hematologic Neoplasms PHASE1 COMPLETED 2025-11-12 Duarte, California, 91010, Uni... More >>ted States|New Brunswick, New Jersey, 08901, United States|New York, New York, 10065, United States|Houston, Texas, 77030, United States|Toronto, Ontario, M5G 2M9, Canada|Montreal, Quebec, H3T 1E2, Canada|Bologna, Emilia-Romagna, 40138, Italy|Roma, Lazio, 00161, Italy|Glasgow, G12 0YN, United Kingdom|Leeds, LS9 7TF, United Kingdom|Oxford, OX3 7LJ, United Kingdom Less <<
NCT00559533 Neoplasms PHASE1 COMPLETED 2025-11-12 Aurora, Colorado, 80045, Unite... More >>d States|Boston, Massachusetts, 02115, United States|New York, New York, 10065, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 98229, United States|Bordeaux, 33076, France|Lyon, 69373, France Less <<
NCT01143740 Sarcoma PHASE1 COMPLETED 2025-03-11 Bordeaux, 33076, France|Lille,... More >> 59020, France|Lyon, 69373, France|Villejuif, 94805, France Less <<
NCT01164033 Neoplasms PHASE1 COMPLETED 2025-05-13 Scottsdale, Arizona, 85258, Un... More >>ited States|Kansas City, Kansas, 66160-7330, United States|Kensignton, Maryland, 20895, United States|Dallas, Texas, 75230, United States|San Antonio, Texas, 98229, United States Less <<
NCT01677780 Myelogenous Leukemia, Chronic,... More >> Neoplasms, Myelogenous Leukemia, Acute Less << PHASE1 COMPLETED 2017-06-26 Sarcoma Oncology Center, Santa... More >> Monica, California, 90403, United States|M.D Anderson Cancer Center; Oncology, Houston, Texas, 77030, United States|Cancer Therapy & Research Ctr; Dept Institute for Drug Development, San Antonio, Texas, 78229, United States|Princess Margaret Hospital, Medical Oncology & Haematology, Toronto, Ontario, M5G 2M9, Canada|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, 31059, France Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.37mL

0.27mL

0.14mL

6.87mL

1.37mL

0.69mL

13.74mL

2.75mL

1.37mL

References

 

Historical Records

Categories